Is buprenorphine transdermal patch equally safe and effective in younger and elderly patients with osteoarthritis-related pain? Results of an age-group controlled study

References

• Heel RC, Brogden RN, Speight TM, et al. Buprenorphine: a review of its pharmacological properties and therapeutic efficacy. Drugs 1979;17:81-110
   PubMed Web of Science ®Google Scholar
• Lewis JW. Buprenorphine. Drug Alcohol Depend 1985;14:363-72
   PubMed Web of Science ®Google Scholar
• Hoskin PJ, Hanks GW. Opioid agonist–antagonist drugs in acute and chronic pain states. Drugs 1991;41:326-44
   PubMed Web of Science ®Google Scholar
• Budd K. Buprenorphine and the transdermal system: the ideal match in pain management. Int J Clin Pract Suppl 2003;133:9-14, discussion 23-4
   PubMedGoogle Scholar
• Conaghan PG, O’Brien CM, Wilson M, et al. Transdermal buprenorphine plus oral paracetamol vs an oral codeine–paracetamol combination for osteoarthritis of hip and/or knee: a randomised trial. Osteoarthritis Cartilage 2011;19:930-8
   PubMed Web of Science ®Google Scholar
• Karlsson M, Berggren AC. Efficacy and safety of low-dose transdermal buprenorphine patches (5, 10 and 20 microg/h) versus prolonged release tramadol tablets (75, 100, 150 and 200 mg) in subjects with chronic osteoarthritis pain: a 12-week, randomized, open-label, controlled, parallel-group noninferiority study. Clin Ther 2009;31:503-13
   PubMed Web of Science ®Google Scholar
• James IG, O’Brien CM, McDonald CJ. A randomised, double-blind, double-dummy comparison of the efficacy and tolerability of low dose transdermal buprenorphine (BuTran s sevenday patches) with buprenorphine sublingual tablets (Temgesic) in patients with osteoarthritis pain. J Pain Symptom Manage 2010;40:266-78
   PubMed Web of Science ®Google Scholar
• Breivik H, Ljosaa TM, Stengaard-Pedersen K, et al. A 6-months, randomised, placebo-controlled evaluation of efficacy and tolerability of a low-dose 7-day buprenorphine transdermal patch in osteoarthritis subjects naïve to potent opioids. Scand J Pain 2010;1:122-41
   PubMedGoogle Scholar
• Murray CJL, Lopez AD, eds. The Global Burden of Disease. A Comprehensive Assessment of Mortality and Disability from Diseases, Injuries, and Risk Factors in 1990 and Projected to 2020. Cambridge (MA): Harvard School of Public Health on behalf of the World Health Organization and The World Bank, 1996
   Google Scholar
• Symmons D, Mathers C, Pfleger B. Global burden of osteoarthritis in the year 2000. Geneva: World Health Organization, 2003. Available at: www.who.int/healthinfo/statistics/bod_osteoarthritis.pdf [Last accessed 29 April 2013]
   Google Scholar
• Arthritis Care. OA Nation: the most comprehensive UK report of people with osteoarthritis. Available at: http://www.arthritiscare.org.uk/PublicationsandResources/Forhealthprofessionals/OANation/Downloads/main_content/@114177 [Last accessed 29 April 2013]
   Google Scholar
• Information from the Medical Products Agency. Treatment of osteoarthritis: treatment recommendations [in Swedish]. 2004;3(15):19-25. Available at: www.mpa.se [Last accessed 16 December 2013]
   Google Scholar
• NICE Clinical Guidelines for Care and Management in Adults – Osteoarthritis. Available at: http://www.nice.org.uk/nicemedia/pdf/CG59NICEguideline.pdf [Last accessed 29 April 2013]
   Google Scholar
• The Swedish Council on Technology Assessment in Health Care. Pharmaceutical treatments among the elderly – how can it be improved? [in Swedish]. Stockholm, Sweden: SBU, 2009
   Google Scholar
• American Geriatric Society (AGS) Panel on pharmacological management of persistent pain in older persons. Pharmacological management of persistent pain in older persons. J Am Geriatr Soc 2009;57:1331-46
   Google Scholar
• Page J, Henry D. Consumption of NSAIDs and the development of congestive heart failure in elderly patients: an underrecognized public health problem. Arch Intern Med 2000;160:777-84
   PubMed Web of Science ®Google Scholar
• Information from the Medical Products Agency. Use of opioids for chronic non-malignant pain -- recommendations [in Swedish]. 2002;1:17-30 . Available at: www.mpa.se [Last accessed 16 December 2013]
   Google Scholar
• The Swedish Council on Technology Assessment in Health Care. Methods for treatment of chronic pain [in Swedish]. Stockholm, Sweden: SBU, 2006
   Google Scholar
• The National Board of Health and Welfare. Swedish guidelines 2010 [in Swedish]: Indikatorer för god läkemedelsterapi hos äldre. 2010, pp 61-65. Available at: www.socialstyrelsen.se [Last accessed 16 December 2013]
   Google Scholar
• European Guidelines for primary care management of chronic osteoarthritis pain. Available at: http://eGuidelines.co.uk [Last accessed 16 December 2013]
   Google Scholar
• Norspan Transdermal Patches. Summary of Product Characteristics; November 2009. Available at www.mpa.se [Last accessed 16 December 2013]
   Google Scholar
• Vadivelu N, Hines RL. Management of chronic pain in the elderly: focus on transdermal buprenorphine. Clin Interv Aging 2008;3:421-30
   PubMed Web of Science ®Google Scholar
• Brewster D, Humphrey MJ, McLeavy MA. Biliary excretion, metabolism and enterohepatic circulation of buprenorphine. Xenobiotica 1981;11:189-96
   PubMed Web of Science ®Google Scholar
• Cone EJ, Gorodetzky CW, Yousefnejad D, et al. The metabolism and excretion of buprenorphine in humans. Drug Metab Dispos 1984;12:577-81
   PubMed Web of Science ®Google Scholar
• Filitz J, Griessinger N, Sittl R, et al. Effects of intermittent hemodialysis on buprenorphine and norbuprenorphine plasma concentrations in chronic pain participants treated with transdermal buprenorphine. Eur J Pain 2006;10:743-8
   PubMed Web of Science ®Google Scholar
• Walsh SL, Preston KL, Stitzer ML, et al. Clinical pharmacology of buprenorphine: ceiling effects at high doses. Cline Pharmacol Ther 1994;55:569-80
   PubMed Web of Science ®Google Scholar
• Johnson RE, Fudala PJ, Payne R. Buprenorphine: considerations for pain management. J Pain Symptom Manage 2005;29:297-326
   PubMed Web of Science ®Google Scholar
• Al-Tawil N, Odar-Cederlöf I, Berggren AC, et al. Pharmacokinetics of transdermal buprenorphine patch in the elderly. Eur J Clin Pharmacol 2013;69:143-9
   PubMed Web of Science ®Google Scholar
• European Medicines Agency, International Conference on Harmonization–World Health Organization. Guideline for Good Clinical Practice [EMA website]. ICH Topic E6. Geneva, Switzerland: WHO, 2002. Available at: www.ema.europa.eu/pdfs/human/ich/013595en.pdf [Last accessed 29 April 2013]
   Google Scholar
• World Medical Association Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects [WMA website]. Ferney-Voltaire, France: WMA, 1989. Available at: www.wma.net/en/30publications/10policies/b3/17c.pdf [Last accessed 29 April 2013]
   Google Scholar
• EMEA: CPMP/EWP/612/00. Note for guidance on clinical investigation of medicinal products for treatment of nociceptive pain. London, 21 November 2002. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003525.pdf [Last accessed 29 April 2013]
   Google Scholar
• Jensen MP, Karoly P, Braver S. The measurement of clinical pain intensity: a comparison of six methods. Pain 1986;27:117-26
   PubMed Web of Science ®Google Scholar
• Jensen MP, Karoly P, O’Riordan EF, et al. The subjective experience of acute pain. An assessment of the utility of 10 indices. Clin J Pain 1989;5:153-9
   PubMed Web of Science ®Google Scholar
• Kremer E, Atkinson JH, Ignelzi RJ. Measurement of pain: patient preference does not confound pain measurement. Pain 1981;10:241-8
   PubMed Web of Science ®Google Scholar
• Szende A, Oppe M, Devlin N (eds). EQ-5D Value Sets: Inventory, Comparatory Review and User Guide. EuroQol Group Monographs Volume 2. The Netherlands: Springer, 2007
   Google Scholar
• Dworkin RH, Turk DC, Wyrwich KW, et al. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. J Pain 2008;9:105-21
   PubMed Web of Science ®Google Scholar
• Farrar JT, Young JP Jr, LaMoreaux L, et al. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical rating scale. Pain 2001;94:149-58
   PubMed Web of Science ®Google Scholar
• Farrar JT, Pritchett YL, Robinson M, et al. The clinical importance of changes in the 0 to 10 Numeric Rating scale for Worst, Least, and Average Pain Intensity: analyses of data from clinical trials of duloxetine in pain disorders. J Pain 2010;11:109-18
   PubMed Web of Science ®Google Scholar
• Davis MP. Twelve reasons for considering buprenorphine as a frontline analgesic in the management of pain. J Support Oncol 2012;10:209-19
   PubMedGoogle Scholar
• Likar R, Vadlau EM, Breschan C, et al. Comparable analgesic efficacy of transdermal buprenorphine in patients over and under 65 years of age. Clin J Pain 2008;24:536-43
   PubMed Web of Science ®Google Scholar
• Muriel Villoria C, Pérez-Castejón Garrote JM, et al. Effectiveness and safety of transdermal buprenorphine for chronic pain treatment in the elderly: a prospective observational study [in Spanish]. Med Clin (Barc) 2007;128:204-10
   PubMed Web of Science ®Google Scholar
• Griessinger N, Sittl R, Likar R. Transdermal buprenorphine in clinical practice – a post-marketing surveillance study in 13,179 patients. Curr Med Res Opin 2005;21:1147-56
   PubMed Web of Science ®Google Scholar
• Gallagher AM, Leighton-Scott J, van Staa TP. Utilization characteristics and treatment persistence in participants prescribed low-dose buprenorphine patches in primary care in the United Kingdom: a retrospective cohort study. Clin Ther 2009;31:1707-15
   PubMed Web of Science ®Google Scholar
• Chevillard L, Mégarbane B, Risède P, et al. Characteristics and comparative severity of respiratory response to toxic doses of fentanyl, methadone, morphine, and buprenorphine in rats. Toxicol Lett 2009;191:327-40
   PubMed Web of Science ®Google Scholar
• Gomez-Flores R, Weber R. Differential effects of buprenorphine and morphine on immune and neuroendocrine functions following acute administration in the rat mesencephalon periaqueductal gray. Immunopharmacology 2000;48:145-56
   PubMed Web of Science ®Google Scholar
• Pergolizzi J, Aloisi AM, Dahan A, et al. Current knowledge of buprenorphone and its unique pharmacological profile. Pain Practice 2010;10:428-50
   PubMed Web of Science ®Google Scholar
• Seripa D, Pilotto A, Panza F, et al. Pharmacogenetics of cytochrome P450 (CYP) in the elderly. Ageing Res Rev 2010;9:457-74
   PubMed Web of Science ®Google Scholar
• Mistry M, Houston JB. Glucuronidation in vitro and in vivo. Comparison of intestinal and hepatic conjugation of morphine, naloxone and buprenorphine. Drug Metab Dispos 1987;15:710-17
   PubMed Web of Science ®Google Scholar